Search Results - "Uronis, H. E."

Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis by Uronis, H E, Currow, D C, McCrory, D C, Samsa, G P, Abernethy, A P

“…The aim of this study was to determine the efficacy of palliative oxygen for relief of dyspnoea in cancer patients. MEDLINE and EMBASE were searched for…”
Get full text

Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial by Wang, J., Liu, S.V., Uronis, H.E., Wu, C., Mahalingam, D., Spira, A., Carter, L., Hu, X., Weems, G., Wilkins, H.J., Duska, L.R., Kelly, K.

Get full text

Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA) by Catenacci, D.V.T., Park, H., Uronis, H.E., Kang, Y.-K., Ng, M., Gold, P., Lacy, J., Enzinger, P.C., Park, S., Lee, K.-W., Yen, J., Odegaard, J., Franovic, A., Baughman, J., Muth, J., Wynter-Horton, A., Wu, T., Wigginton, J., Davidson-Moncada, J.K., Bang, Y.-J.

Get full text

Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis? by Jaffe, T. A., Neville, A. M., Bashir, M. R., Uronis, H. E., Thacker, J. M.

“…Aim Patients with rectal cancer often undergo multiple CT scans prior to surgical resection. We propose that in patients with locally advanced rectal cancer…”
Get full text

1139PDNovel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial by Wang, J, Liu, S V, Uronis, H E, Wu, C, Mahalingam, D, Spira, A, Carter, L, Hu, X, Weems, G, Wilkins, H J, Duska, L R, Kelly, K

Get full text

662PBiomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA) by Catenacci, D V T, Park, H, Uronis, H E, Kang, Y-K, Ng, M, Gold, P, Lacy, J, Enzinger, P C, Park, S, Lee, K-W, Yen, J, Odegaard, J, Franovic, A, Baughman, J, Muth, J, Wynter-Horton, A, Wu, T, Wigginton, J, Davidson-Moncada, J K, Bang, Y-J

Get full text

A phase I study of erlotinib, bevacizumab, and external beam radiation therapy (RT) for patients with localized pancreatic carcinoma (PC) by Czito, B. G., Willett, C., Kennedy-Newton, P., Tyler, D. S., Hurwitz, H., Uronis, H. E.

“…Abstract only 281 Background: Localized PC is commonly managed with chemoradiotherapy, with or without surgical resection. The optimal combination of agents…”
Get full text

Carcinoma of the ampulla of Vater: Patterns of failure after resection and benefit of adjuvant radiotherapy by Palta, M., Willett, C. G., Patel, P., Tyler, D. S., Uronis, H. E., Czito, B. G.

“…Abstract only 254 Background: Ampullary carcinoma is a rare malignancy. Despite radical resection, survival rates remain low with high rates of local failure…”
Get full text

Single-institution experience of preoperative chemoradiotherapy for locally advanced gastric cancer by Pepek, J. M., Chino, J. P., Willett, C. G., Tyler, D. S., Uronis, H. E., Czito, B. G.

“…Abstract only 99 Background: To examine acute toxicity and outcomes for patients treated with preoperative chemoradiotherapy (CRT) for gastric cancer. Methods:…”
Get full text

Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer by Starodub, A., Cohn, A. L., Arrowood, C., Haley, S., Morse, M., Uronis, H. E., Blobe, G. C., Hsu, S. D., Zafar, Y., Hurwitz, H.

“…Abstract only 513 Background: SRC is a non-receptor tyrosine kinase involved in normal and tumor cell signaling functions including cell proliferation,…”
Get full text

Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study 265-101) by Drouin, M. A., Kollmannsberger, C. K., Uronis, H. E., Martell, R. E., Wang, J., Dubay, M., Dupont, I., Besterman, J. M., Hurwitz, H., Shapiro, G.

“…Abstract only…”
Get full text

Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC) by Altomare, I., Russell, K. B., Uronis, H. E., Morse, M., Hsu, S. D., Zafar, Y., Bendell, J. C., Starodub, A., Honeycutt, W., Hurwitz, H.

“…Abstract only…”
Get full text

A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors by Uronis, H. E., Bullock, K., Blobe, G., Hsu, S., Morse, M., Nixon, A., Haley, S., O’Neill, M., Hurwitz, H., Bendell, J.

“…Abstract only e15506 Background: Dasatinib (D) is a small molecule tyrosine kinase inhibitor with activity against both bcr-abl and src. Cetuximab (C) is a…”
Get full text

Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors by Howard, L. A., Bullock, K. E., Bendell, J. C., Uronis, H. E., Vlahovic, G., Blobe, G. C., Riedel, R. F., Nixon, A. B., Gockerman, J. P., Hurwitz, H. I.

“…Abstract only 3551 Background: In preclinical models, VEGF, mTOR, and EGFR inhibitors have anti-tumor and anti-angiogenesis effects as monotherapies and in…”
Get full text

Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC) by Bullock, K. E., Hurwitz, H. I., Uronis, H. E., Morse, M. A., Blobe, G. C., Hsu, S. D., Zafar, S. Y., Nixon, A. B., Howard, L. A., Bendell, J. C.

“…Abstract only 4080 Background: For patients (pts) with mCRC, no standard therapy exists after progression on 5-FU, oxaliplatin, irinotecan, bevacizumab, and/or…”
Get full text

E/Tablets to collect research-quality, patient-reported data by Uronis, H. E., Herndon, J. E., Coan, A., Bronson, K., Wheeler, J., Lyerly, H. K., Morse, M. A., Abernethy, A. P.

“…Abstract only…”
Get full text

Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC) by Bendell, J. C., Uronis, H. E., Morse, M. A., Blobe, G., Aklilu, M., Nixon, A., Niedzweicki, D., Honeycutt, W., Howard, L., Hurwitz, H.

“…Abstract only…”
Get full text

Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer? by Hurwitz, Herbert I, Uronis, Hope E

Get full text

A phase I study of bevacizumab (BV) plus ABT-510 in patients with advanced solid tumors by Uronis, H. E., Bendell, J., Blobe, G., Morse, M., Geier, D., Nixon, A., Howard, L., Evans, D., Li, H., Hurwitz, H.

“…Abstract only 3541 Background: BV is a potent inhibitor of vascular endothelial growth factor (VEGF) with broad clinical activity both alone and in…”
Get full text